Adlai Nortye Group (ANL) vs Lexicon Pharmaceuticals (LXRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 17, 2026.
Summary
Adlai Nortye Group (ANL) has outperformed Lexicon Pharmaceuticals (LXRX) over the past year, gaining 572.6% versus a gain of 7.0%. Adlai Nortye Group is the larger company by market cap ($710.3 million vs $676.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANL | LXRX |
|---|---|---|
| Share price | $11.03 | $1.52 |
| Market cap | $710.31M | $676.33M |
| 1-day change | -8.77% | -7.88% |
| YTD return | +676.76% | +32.17% |
| 1-year return | +572.56% | +7.04% |
| 5-year return | — | -70.20% |
| EPS (TTM) | $-0.66 | $-0.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $49.80M |
| Revenue growth (YoY) | — | +60.24% |
| Net income (latest FY) | $-51.87M | $-50.34M |
| Gross margin | — | 99.45% |
| Operating margin | — | -98.21% |
| Net margin | — | -101.08% |
| 52-week high | $17.25 | $2.68 |
| 52-week low | $0.879 | $1.10 |
| Distance from 52-week high | -36.06% | -43.28% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +167.45% | +199.34% |
| Average volume | 212.90K | 2.84M |
| Shares outstanding | 58.73M | 444.96M |
| Employees | 109 | 81 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANL has outperformed LXRX by 565.5 percentage points over the past year.
About Adlai Nortye Group
ANL stock →Adlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies. The company's pipeline centers on RAS-targeting therapies and next-generation cancer immunotherapies.
Health Care · Biotechnology: Pharmaceutical Preparations · 109 employees
About Lexicon Pharmaceuticals
LXRX stock →Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes.
Health Care · Biotechnology: Pharmaceutical Preparations · 81 employees
ANL vs LXRX FAQ
Which is bigger, Adlai Nortye Group or Lexicon Pharmaceuticals?
Adlai Nortye Group (ANL) is larger, with a market capitalization of $710.31M compared with $676.33M for Lexicon Pharmaceuticals (LXRX).
Which stock has performed better over the past year, ANL or LXRX?
ANL returned +572.56% over the past 12 months, compared with +7.04% for LXRX (price return, excluding dividends). Past performance does not predict future results.
Are Adlai Nortye Group and Lexicon Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.